证券日报网讯 8月20日晚间，川宁生物发布公告称，近日，公司完成了伊犁川宁生物技术股份有限公司 2025年度第一期科技创新债券（乡村振兴）的发行，扣除承销费10，136.99元后募集资金净额199， 989，863.01元已于2025年8月20日到账，将用于补充营运资金。 （编辑 楚丽君） ...

公司于 2025 年 2 月 5 日收到中国银行间市场交易商协会（以下简称"交易商协 会"）出具的《接受注册通知书》（中市协注〔2025〕SCP20 号），交易商协会同意接 受公司超短期融资券的注册，注册金额为人民币 10 亿元，注册额度自通知书落款之 日起 2 年内有效。 近日，公司完成了伊犁川宁生物技术股份有限公司 2025 年度第一期科技创新债 券（乡村振兴）（简称"本期债券"）的发行，扣除承销费 10,136.99 元后募集资金净 额 199,989,863.01 元已于 2025 年 8 月 20 日到账，将用于补充营运资金。本期债券由 兴业银行股份有限公司为主承销商组织承销团，通过簿记建档、集中配售的方式在 全国银行间债券市场公开发行，现将发行结果公告如下： | | 发行要素 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 债券名称 | 伊犁川宁生物技术股份有 限公司 技创新债券（乡村振兴） | 2025 | 年度第一期科 | 债券简称 | 25 | 川宁生物 | SCP001(科创债) | | 债券代码 | 01 ...

金融界消息 截至2025年8月12日收盘，川宁生物（301301）报收于12.28元，下跌0.73%，换手率 3.08%，成交量19.06万手，成交金额2.34亿元。 资金流向方面，今日主力资金净流出3328.78万元，占比成交额14.22%。其中，超大单净流出1398.08万 元、占成交额5.97%，大单净流出1930.69万元、占成交额8.25%，中单净流出流入1124.56万元、占成交 额4.81%，小单净流入2204.22万元、占成交额9.42%。 川宁生物最新一期业绩显示，截至2025一季报，公司营业总收入12.97亿元、同比减少14.85%，归属净 利润2.88亿元，同比减少18.26%，扣非净利润2.83亿元，同比减少19.55%，流动比率2.239、速动比率 1.648、资产负债率23.53%。 天眼查商业履历信息显示，伊犁川宁生物技术股份有限公司，成立于2010年，位于伊犁哈萨克自治州， 是一家以从事医药制造业为主的企业。企业注册资本222716万人民币，实缴资本198453.9326万人民 币。公司法定代表人为邓旭衡。 通过天眼查大数据分析，伊犁川宁生物技术股份有限公司共对外投资了14家企 ...

随着中国居民健康意识不断增强，我国生物医药产业保持高速增长势头，相关上市公司业绩也水涨船 高。 据Wind数据统计，截至1月16日记者发稿，深市共有14家医疗保健企业（以Wind一级行业分类标准划 分）披露了2023年业绩预告。其中，12家净利润预计实现正增长，占比85.71%。康泰生物、贝达药 业、川宁生物暂列净利润增长榜单前三位，预计分别增长（以上限计算）815.86%、154.43%和 140.57%。 2023年中央经济工作会议提出，打造生物制造、商业航天、低空经济等若干战略性新兴产业，开辟量 子、生命科学等未来产业新赛道，广泛应用数智技术、绿色技术，加快传统产业转型升级。 在此背景下，生物医药产业迎来发展黄金期，"高成长"已然成为其鲜明标签，一众优秀企业代表不断涌 现。 例如，川宁生物1月15日晚间发布业绩预告称，2023年公司预计实现归属于上市公司股东的净利润9亿元 至9.9亿元，同比增长118.7%至140.57%；预计实现扣除非经常性损益后的净利润为9亿元至9.9亿元，同 比增长101.51%至121.66%。 贝达药业2023年年度业绩预告显示，公司预计实现归属于上市公司股东净利润3.20亿 ...

Core Viewpoint - The financial performance of Chuaning Biological (川宁生物) shows a decline in revenue and net profit for the first quarter of 2025, indicating potential challenges for the company moving forward [1]. Financial Performance - As of the first quarter of 2025, Chuaning Biological reported total revenue of 1.297 billion yuan, a year-on-year decrease of 14.85% [1]. - The net profit attributable to shareholders was 288 million yuan, down 18.26% year-on-year [1]. - The company's non-recurring net profit was 283 million yuan, reflecting a 19.55% decrease compared to the previous year [1]. - The liquidity ratios are as follows: current ratio at 2.239 and quick ratio at 1.648, indicating a strong liquidity position [1]. - The debt-to-asset ratio stands at 23.53%, suggesting a relatively low level of financial leverage [1]. Stock Performance - As of August 8, 2025, Chuaning Biological's stock closed at 12.2 yuan, down 1.21% with a turnover rate of 4.73% [1]. - The trading volume was 292,700 hands, with a total transaction value of 357 million yuan [1]. - There was a net outflow of main funds amounting to 42.93 million yuan, which accounted for 12.03% of the transaction value [1]. - Large orders saw a net outflow of 23.74 million yuan (6.65% of transaction value) and 19.19 million yuan (5.38% of transaction value) for big orders [1]. - Small orders experienced a net inflow of 46.36 million yuan, representing 12.99% of the transaction value [1]. Company Background - Chuaning Biological Technology Co., Ltd. was established in 2010 and is located in the Ili Kazakh Autonomous Prefecture [2]. - The company primarily engages in the pharmaceutical manufacturing industry [2]. - The registered capital of the company is 2.22716 billion yuan, with paid-in capital of approximately 1.98454 billion yuan [1][2]. - The legal representative of the company is Deng Xuheng [1]. Investment and Intellectual Property - Chuaning Biological has made investments in 14 companies and participated in 41 bidding projects [2]. - The company holds 9 trademark registrations and 154 patents, along with 41 administrative licenses [2].

Group 1 - The company currently has all three antibiotic product lines operating at full capacity [2] - There are no plans for new production lines or new product launches at this time [2]

Group 1 - The core viewpoint of the article is that Chuaning Bio (301301.SZ) has all three production lines for its major antibiotic products operating at full capacity, indicating strong production efficiency and demand [1] - The company currently has no plans for new production line construction, suggesting a focus on optimizing existing operations rather than expanding capacity [1]

Core Viewpoint - Chuaning Bio (301301.SZ) has indicated that its ergot alkaloid products are currently produced on a flexible synthetic biology production line, which has not yet reached full production capacity, but the current output is sufficient to meet market demand [1] Company Summary - Chuaning Bio's ergot alkaloid products are produced using a synthetic biology approach [1] - The production line for these products is not yet operating at full capacity [1] - Despite the production line's status, the company is able to meet the current market needs for ergot alkaloids [1]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]